Why the study?
Does the swine influenza vaccine increase the risk of Guillain-Barré syndrome?
Does the swine influenza vaccine increase the risk of Guillain-Barré syndrome?
The 1976-1977 swine influenza vaccine was associated with a significantly increased risk of extensive Guillain-Barré syndrome for up to 8 weeks post-vaccination.
Answers are grounded in this paper and cite their sources.
Supports historical GBS association with swine flu vaccine; leaves open relevance to modern influenza formulations.
As a result of a court order, computerized summaries of approximately 1,300 cases reported as Guillain-Barré syndrome by state health departments to the Centers for Disease Control during the intensive national surveillance instituted following the swine influenza vaccination program in 1976-1977 became available for further study. Although the data were not uniformly adequate to confirm the diagnosis of Guillain-Barré syndrome, they were sufficient to enable classification according to extent of motor involvement. Vaccinated cases with "extensive" paresis or paralysis occurred in a characteristic epidemiologic pattern closely approximated by a lognormal curve, suggesting a causal relationship between the disease and the vaccine. Cases with "limited" motor involvement showed no such pattern, suggesting that this group included a substantial proportion of cases which were unrelated to the vaccine. The effect attributed to the vaccine lasted for at least six weeks and possibly for eight weeks but not longer. The relative risk of acquiring "extensive" disease over a six-week period following vaccination ranged from 3.96 to 7.75 depending on the particular baseline estimate of expected normal or endemic incidence that was chosen. Correspondingly, the number of cases that could be attributed to the vaccine over the six-week period ranged from 211 to 246, or very slightly higher over an eight-week period if the lowest baseline estimate was used. The total rate of Guillain-Barré syndrome cases attributed to prior use of the vaccine was 4.9 to 5.9 per million vaccinees.
No takes yet. Share an insight, caveat, or question.
Langmuir et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: